| Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice A Swidsinski, V Loening-Baucke, H Lochs, LP Hale World journal of gastroenterology: WJG 11 (8), 1131, 2005 | 1236* | 2005 |
| Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial K Nakagawa, EB Garon, T Seto, M Nishio, SP Aix, L Paz-Ares, CH Chiu, ... The Lancet Oncology 20 (12), 1655-1669, 2019 | 537 | 2019 |
| KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target M Román, I Baraibar, I López, E Nadal, C Rolfo, S Vicent, I Gil-Bazo Molecular cancer 17, 1-14, 2018 | 340 | 2018 |
| Liquid biopsies in lung cancer: the new ambrosia of researchers C Rolfo, M Castiglia, D Hong, R Alessandro, I Mertens, G Baggerman, ... Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1846 (2), 539-546, 2014 | 224 | 2014 |
| Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis M Duruisseaux, A Martínez-Cardús, ME Calleja-Cervantes, S Moran, ... The Lancet Respiratory Medicine 6 (10), 771-781, 2018 | 192 | 2018 |
| Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway S Taverna, M Pucci, M Giallombardo, MA Di Bella, M Santarpia, ... Scientific reports 7 (1), 3170, 2017 | 148 | 2017 |
| Entrectinib: a potent new TRK, ROS1, and ALK inhibitor C Rolfo, R Ruiz, E Giovannetti, I Gil-Bazo, A Russo, F Passiglia, ... Expert opinion on investigational drugs 24 (11), 1493-1500, 2015 | 145 | 2015 |
| Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients ME Rodriguez-Ruiz, JL Perez-Gracia, I Rodriguez, C Alfaro, C Oñate, ... Annals of Oncology 29 (5), 1312-1319, 2018 | 125 | 2018 |
| Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis A Calvo, R Catena, MS Noble, D Carbott, I Gil-Bazo, O Gonzalez-Moreno, ... Oncogene 27 (40), 5373-5384, 2008 | 123 | 2008 |
| Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice S Taverna, M Giallombardo, I Gil-Bazo, AP Carreca, M Castiglia, ... Oncotarget 7 (19), 28748, 2016 | 118 | 2016 |
| Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB) C Rolfo, AF Cardona, M Cristofanilli, L Paz-Ares, JJD Mochon, I Duran, ... Critical Reviews in Oncology/Hematology 151, 102978, 2020 | 106 | 2020 |
| Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors C Rolfo, E Giovannetti, DS Hong, T Bivona, LE Raez, G Bronte, L Buffoni, ... Cancer treatment reviews 40 (8), 990-1004, 2014 | 104 | 2014 |
| Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array JL Perez-Gracia, C Prior, F Guillén-Grima, V Segura, A Gonzalez, ... British journal of cancer 101 (11), 1876-1883, 2009 | 99 | 2009 |
| Reassessment of id1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-id1 antibody J Perk, I Gil-Bazo, Y Chin, P de Candia, JJS Chen, Y Zhao, S Chao, ... Cancer research 66 (22), 10870-10877, 2006 | 98 | 2006 |
| TGFBI expression is associated with a better response to chemotherapy in NSCLC M Irigoyen, MJ Pajares, J Agorreta, M Ponz-Sarvisé, E Salvo, MD Lozano, ... Molecular Cancer 9, 1-12, 2010 | 97 | 2010 |
| Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade D Ajona, S Ortiz-Espinosa, T Lozano, F Exposito, A Calvo, K Valencia, ... Nature Cancer 1 (1), 75-85, 2020 | 93 | 2020 |
| PD-1/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice I Eguren-Santamaria, MF Sanmamed, SB Goldberg, HM Kluger, ... Clinical Cancer Research 26 (16), 4186-4197, 2020 | 76 | 2020 |
| Targeting hypoxia and angiogenesis through HIF-1alpha inhibition JA Diaz-Gonzalez, J Russell, A Rouzaut, I Gil-Bazo, L Montuenga Cancer biology & therapy 4 (10), 1055-1062, 2005 | 74 | 2005 |
| Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice JH Jang, L Baerts, Y Waumans, I De Meester, Y Yamada, P Limani, ... Clinical & experimental metastasis 32, 677-687, 2015 | 69 | 2015 |
| YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib I Garmendia, MJ Pajares, F Hermida-Prado, D Ajona, C Bértolo, C Sainz, ... American journal of respiratory and critical care medicine 200 (7), 888-899, 2019 | 65 | 2019 |
